Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.05 | 1.9 |
NAV | ₹19.08 | ₹38.59 |
Fund Started | 06 Oct 2020 | 25 Jun 2018 |
Fund Size | ₹156.35 Cr | ₹5507.52 Cr |
Exit Load | - | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 7.49% | 20.37% |
3 Year | 20.33% | 29.86% |
5 Year | - | 24.19% |
1 Year
3 Year
5 Year
Equity | 99.95% | 96.99% |
Cash | -0.07% | 3.01% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.29% |
Max Healthcare Institute Ltd. | 6.68% |
Divi's Laboratories Ltd. | 6.03% |
Cipla Ltd. | 5.87% |
Dr. Reddy's Laboratories Ltd. | 5.58% |
Apollo Hospitals Enterprise Ltd. | 5.29% |
Eli Lilly And Co | 4.86% |
Lupin Ltd. | 3.41% |
Johnson & Johnson Ltd. | 3.05% |
Torrent Pharmaceuticals Ltd. | 2.87% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.66% |
Dr. Reddy's Laboratories Ltd. | 9.66% |
Divi's Laboratories Ltd. | 9.03% |
Cipla Ltd. | 7.85% |
Aurobindo Pharma Ltd. | 6.34% |
Alkem Laboratories Ltd. | 4.12% |
Zydus Lifesciences Ltd. | 4.01% |
Lupin Ltd. | 3.98% |
Gland Pharma Ltd. | 3.95% |
Syngene International Ltd. | 2.46% |
Name | Bhavesh Jain | Dharmesh Kakkad |
Start Date | 01 Oct 2021 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 06 Oct 2020 | 25 Jun 2018 |
Description
Launch Date